Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up
Open Access
- 26 May 2013
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 24 (9), 2434-2438
- https://doi.org/10.1093/annonc/mdt181
Abstract
Splenic marginal zone lymphoma with or without villous lymphocytes (SLVL/SMZL) is an indolent lymphoma that typically affects elderly patients and that has a median survival >10 years. It presents with marked splenomegaly. Treatment is required in symptomatic cases. Splenectomy remains one of the first-line options in patients fit for surgery. The best pharmacological strategy has not yet been identified for poor surgical risk cases. Among different possible chemotherapeutic approaches, purine analogs, alone or in association with Rituximab, seem to be a valid therapeutic choice. Fifty SMZL patients were treated with Cladribine ± anti-CD20 monoclonal antibody. Forty-seven of 50 patients were evaluable for response. ORR was 87%: 24 of 47 patients (51%) achieved a complete hematological response (CR), 17 of 47 (36%) a partial response (PR) and 6 (13%) resulted unresponsive. Interestingly, 15 of 24 cases (62%) in CR achieved also a molecular remission. After a median follow-up of 48 months, 7 of 41 responsive cases relapsed and the 5-year PFS was 80%. These data confirm the efficacy of this schedule emphasizing the impact of minimal residual disease even in the outcome of SMZL patients.This publication has 24 references indexed in Scilit:
- Splenic marginal zone lymphoma: a prognostic model for clinical useBlood, 2006
- Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomasLeukemia, 2004
- Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytesBritish Journal of Haematology, 2003
- Splenic marginal-zone lymphoma: a distinct clinical and pathological entityThe Lancet Oncology, 2003
- Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus InfectionThe New England Journal of Medicine, 2002
- Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytesCancer, 2001
- Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patientsBlood, 2000
- Marginal Zone B-Cell Lymphoma: A Clinical Comparison of Nodal and Mucosa-Associated Lymphoid Tissue TypesJournal of Clinical Oncology, 1999
- Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytesBritish Journal of Haematology, 1997
- Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patientsBritish Journal of Haematology, 1996